Gimeracil (BioDeep_00000179413)
human metabolite blood metabolite
代谢物信息卡片
5-chloro-4-hydroxy-1,2-dihydropyridin-2-one
化学式: C5H4ClNO2 (144.9930554)
中文名称: 吉美拉西
谱图信息:
最多检出来源 Danio rerio(blood) 13.24%
分子结构信息
SMILES: C1=C(C(=CNC1=O)Cl)O
InChI: InChI=1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)
描述信息
C471 - Enzyme Inhibitor > C2019 - Dihydropyrimidine Dehydrogenase Inhibitor
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:31652
- PubChem: 54679224
- HMDB: HMDB0252719
- DrugBank: DB09257
- ChEMBL: CHEMBL1730601
- chemspider: 3353
- CAS: 1349387-07-0
- CAS: 103766-25-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yoshitaka Saito, Yoh Takekuma, Satoshi Takeuchi, Yoshito Komatsu, Mitsuru Sugawara. Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
International journal of clinical pharmacology and therapeutics.
2021 Dec; 59(12):787-793. doi:
10.5414/cp204091. [PMID: 34503646] - Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
BMC cancer.
2021 Jul; 21(1):796. doi:
10.1186/s12885-021-08487-z. [PMID: 34243732] - Hae Won Lee, Sook Jin Seong, Woo Youl Kang, Boram Ohk, Mi-Ri Gwon, Bo Kyung Kim, Seungil Cho, Kyunghee Cho, Yong Kyung Sung, Young-Ran Yoon, Jong Gwang Kim. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Drug design, development and therapy.
2019; 13(?):3127-3136. doi:
10.2147/dddt.s219822. [PMID: 31564829] - Tae Hwan Kim, Soyoung Shin, Jeong Cheol Shin, Jürgen B Bulitta, Kwon-Yeon Weon, Sun Dong Yoo, Gi-Young Park, Seok Won Jeong, Dong Rak Kwon, Byung Sun Min, Mi Hee Woo, Beom Soo Shin. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
Molecules (Basel, Switzerland).
2017 Sep; 22(9):. doi:
10.3390/molecules22091488. [PMID: 28880240] - Kenta Shimokawa, Kazumi Wakasugi, Rei Tomonaga, Ken Utsunomiya, Hirotaka Miyamoto, Shintaro Fumoto, Koyo Nishida. Effect of Metabolic Inhibitors on the Hepatic Disposition of 5-Fluorouracil after Application to the Rat Liver Surface.
Biological & pharmaceutical bulletin.
2016; 39(3):361-7. doi:
10.1248/bpb.b15-00757. [PMID: 26934928] - Takatsugu Yamamoto, Toru Miyazaki, Yukiko Kurashima, Kazunori Ohata, Masato Okawa, Shogo Tanaka, Takahiro Uenishi, Koichi Ohno. [A Case Report of Successful Chemotherapy with Tegafur/Gimeracil/Oteracil and Nab-Paclitaxel for Gastric Cancer with Chronic Renal Failure].
Gan to kagaku ryoho. Cancer & chemotherapy.
2015 Jun; 42(6):735-8. doi:
. [PMID: 26199247] - Long-Hao Li, Hang Dong, Feng Zhao, Jie Tang, Xin Chen, Jing Ding, Hai-Tao Men, Wu-Xia Luo, Yang Du, Jun Ge, Ben-Xu Tan, Dan Cao, Ji-Yan Liu. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
European journal of cancer (Oxford, England : 1990).
2013 May; 49(7):1752-60. doi:
10.1016/j.ejca.2012.12.013. [PMID: 23313143] - Yu Nishijima, Haruhiko Hirata, Aiko Himeno, Hiroshi Kida, Masanori Matsumoto, Ryo Takahashi, Yasushi Otani, Kouji Inoue, Izumi Nagatomo, Yoshito Takeda, Takashi Kijima, Isao Tachibana, Yoshihiro Fujimura, Atsushi Kumanogoh. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Internal medicine (Tokyo, Japan).
2013; 52(10):1111-4. doi:
10.2169/internalmedicine.52.9180. [PMID: 23676600] - He-ying Liu, Li Ding, Yong Yu, Yan Chu, He Zhu. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Yao xue xue bao = Acta pharmaceutica Sinica.
2012 Oct; 47(10):1363-9. doi:
NULL. [PMID: 23289150] - Tsuyoshi Shoji, Makoto Sonobe, Hiroaki Sakai, Takuji Fujinaga, Toshihiko Sato, Fengshi Chen, Ryo Miyahara, Toru Bando, Hiromi Wada, Hiroshi Date. Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Reviews on recent clinical trials.
2012 May; 7(2):167-72. doi:
10.2174/157488712800100260. [PMID: 22353201] - He-ying Liu, Li Ding, Yong Yu, Yan Chu, He Zhu. Comparison of three derivatization reagents for the simultaneous determination of highly hydrophilic pyrimidine antitumor agents in human plasma by LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Apr; 893-894(?):49-56. doi:
10.1016/j.jchromb.2012.02.033. [PMID: 22429875] - M Wada, M Yamamoto, S Ryuge, Y Nagashima, N Hayashi, S Maki, S Otani, K Katono, A Takakura, T Yanaihara, S Igawa, M Yokoba, H Mitsufuji, M Kubota, M Katagiri, N Masuda. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology.
2012 Apr; 69(4):1005-11. doi:
10.1007/s00280-011-1795-5. [PMID: 22160350] - M Takagi, K Sakata, M Someya, Y Matsumoto, H Tauchi, M Hareyama, M Fukushima. The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
2012 Mar; 188(3):255-61. doi:
10.1007/s00066-011-0043-6. [PMID: 22322869] - Yuichi Ando, Kenji Kawada, Megumi Inada, Sachi Morita, Ayako Mitsuma, Yoshinari Yasuda, Mariko Hiramatsu, Yasushi Fujimoto, Ken-ichi Fujita. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Oncology.
2012; 83(1):38-44. doi:
10.1159/000337232. [PMID: 22722580] - Qing-chao Zhu, Zhi-ming Jin. [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Zhonghua zhong liu za zhi [Chinese journal of oncology].
2011 May; 33(5):388-90. doi:
NULL. [PMID: 21875473] - M W Saif, L S Rosen, K Saito, C Zergebel, L Ravage-Mass, D S Mendelson. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Anticancer research.
2011 Feb; 31(2):625-32. doi:
. [PMID: 21378348] - Seiji Naito, Taiji Tsukamoto, Michiyuki Usami, Hiroyuki Fujimoto, Hideyuki Akaza. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Cancer chemotherapy and pharmacology.
2010 Nov; 66(6):1065-70. doi:
10.1007/s00280-010-1262-8. [PMID: 20157711] - Ke Liu, Dafang Zhong, Huiyu Zou, Xiaoyan Chen. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2010 Aug; 52(4):550-6. doi:
10.1016/j.jpba.2010.01.026. [PMID: 20138454] - Yukimoto Ishii, Shigeru Suzuki, Yasuo Takahashi, Tadatoshi Takayama, Satoshi Asai. Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?.
Cancer chemotherapy and pharmacology.
2010 Jul; 66(2):333-43. doi:
10.1007/s00280-009-1168-5. [PMID: 19921195] - Xiaofan Zhang, Julia Li Zhong, Wei Liu, Zuhua Gao, Xia Xue, Pan Yue, Limei Wang, Cuirong Zhao, Wenfang Xu, Xianjun Qu. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Cancer chemotherapy and pharmacology.
2010 May; 66(1):11-9. doi:
10.1007/s00280-009-1128-0. [PMID: 19756602] - Sayaka Azuma, Shigefumi Morimoto, Kunihiko Kagawa, Yoshinori Katada, Kenji Hasegawa, Katsuyoshi Tabuse. [Construction of a system for proper TS-1 application].
Gan to kagaku ryoho. Cancer & chemotherapy.
2010 Mar; 37(3):469-72. doi:
NULL. [PMID: 20332685] - Hei-Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Japanese journal of clinical oncology.
2010 Jan; 40(1):29-35. doi:
10.1093/jjco/hyp124. [PMID: 19880858] - Yuan Gu, Rong Lu, Duanyun Si, Changxiao Liu. Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
2009 Oct; 25(10):1211-5. doi:
10.2116/analsci.25.1211. [PMID: 19822965] - K Fujita, H Nakayama, W Ichikawa, W Yamamoto, H Endo, F Nagashima, R Tanaka, T Miya, Y Sunakawa, K Yamashita, K Mizuno, H Ishida, K Araki, M Narabayashi, K Miwa, Y Ando, Y Akiyama, K Kawara, T Hirose, Y Sasaki. Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Drug metabolism and disposition: the biological fate of chemicals.
2009 Jul; 37(7):1375-7. doi:
10.1124/dmd.109.027052. [PMID: 19389859] - Akio Ooyama, Toshinori Oka, Hong-ye Zhao, Masatatsu Yamamoto, Shin-ichi Akiyama, Masakazu Fukushima. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
Cancer letters.
2008 Aug; 267(1):26-36. doi:
10.1016/j.canlet.2008.03.008. [PMID: 18420342] - Aiko Tsuda, Junshin Fujiyama, Akiko Miki, Satoko Hori, Hisakazu Ohtani, Yasufumi Sawada. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.
Cancer chemotherapy and pharmacology.
2008 Aug; 62(3):427-32. doi:
10.1007/s00280-007-0621-6. [PMID: 18026730] - Ken-ichi Fujita, Wataru Yamamoto, Shoji Endo, Hisashi Endo, Fumio Nagashima, Wataru Ichikawa, Ryuhei Tanaka, Toshimichi Miya, Kazuhiro Araki, Keiji Kodama, Yu Sunakawa, Masaru Narabayashi, Keisuke Miwa, Yuichi Ando, Yuko Akiyama, Kaori Kawara, Tetsuya Kamataki, Yasutsuna Sasaki. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Cancer science.
2008 May; 99(5):1049-54. doi:
10.1111/j.1349-7006.2008.00773.x. [PMID: 18380793] - Mitsugu Kochi, Masashi Fujii, Noriaki Kanamori, Teruo Kaiga, Kazuo Aizaki, Toru Takahashi, Tadatoshi Takayama. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Cancer chemotherapy and pharmacology.
2007 Oct; 60(5):693-701. doi:
10.1007/s00280-007-0415-x. [PMID: 17690883] - Saori Inoue, Hisakazu Ohtani, Masayuki Tsujimoto, Satoko Hori, Yasufumi Sawada. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Drug metabolism and pharmacokinetics.
2007 Jun; 22(3):162-8. doi:
10.2133/dmpk.22.162. [PMID: 17603216] - Yoshifumi Nakayama, Kentaro Matsumoto, Yuzuru Inoue, Takefumi Katsuki, Koji Kadowaki, Kazunori Shibao, Yosuke Tsurudome, Keiji Hirata, Tatsuhiko Sako, Naoki Nagata, Hideaki Itoh. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
Anticancer research.
2006 Sep; 26(5B):3983-8. doi:
. [PMID: 17094430] - Takashi Oshima, Roppei Yamada, Shinsuke Hatori, Chikara Kunisaki, Toshio Imada. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oncology reports.
2006 Aug; 16(2):361-6. doi:
10.3892/or.16.2.361. [PMID: 16820916] - Koichi Hirata, Noboru Horikoshi, Kazusaku Tominaga, Keisuke Sohma, Koji Yamaguchi, Minoru Okazaki, Tomohisa Furuhata, Kazuaki Sasaki, Yasuyuki Nakano, Hikaru Ishizuka, Yasuhide Yamada, Shinji Uno, Tetsuo Taguchi, Susumu Yamamitsu, Tetsuhiko Shirasaka. [Pharmacokinetics of S-1].
Gan to kagaku ryoho. Cancer & chemotherapy.
2006 Jun; 33 Suppl 1(?):27-35. doi:
NULL. [PMID: 16897969] - Kazuyoshi Yamamoto, Hiroshi Imamura, Hiroshi Furukawa, Tomono Kishimoto, Junichi Tanaka, Ryota Oshiro, Masayuki Tatsuta, Seizo Masutani, Mutsumi Fukunaga, Takahiro Nakayama, Hiroyoshi Takemoto, Motoi Kondo, Shunji Kamigaki, Takatoshi Kawasaki. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Gan to kagaku ryoho. Cancer & chemotherapy.
2005 Oct; 32(11):1748-51. doi:
NULL. [PMID: 16315929] - Toshikazu Tanaka, Shoichi Fujita, Noriko Tanaka, Masaru Ooka, Shiro Okajima, Noriaki Tanaka. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Gan to kagaku ryoho. Cancer & chemotherapy.
2005 Jun; 32(6):841-5. doi:
. [PMID: 15984528] - Godefridus J Peters, Paul Noordhuis, Cornelis J Van Groeningen, Giuseppe Giaccone, Ulbe Holwerda, Daphne Voorn, Ad Schrijvers, Jan H Schornagel, Jos H Beijnen, Pierre Fumoleau, Jan H M Schellens. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Jun; 10(12 Pt 1):4072-6. doi:
10.1158/1078-0432.ccr-1076-03. [PMID: 15217941] - Patrick Schöffski. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Anti-cancer drugs.
2004 Feb; 15(2):85-106. doi:
10.1097/00001813-200402000-00001. [PMID: 15075664] - Kazunari Tominaga, Kazuhide Higuchi, Hirotoshi Okazaki, Reiko Suto, Masaki Hamaguchi, Tetsuya Tanigawa, Eiji Sasaki, Masatsugu Shiba, Toshio Watanabe, Yasuhiro Fujiwara, Nobuhide Oshitani, Takayuki Matsumoto, Tetsuo Arakawa. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Oncology.
2004; 66(5):358-64. doi:
10.1159/000079483. [PMID: 15331922] - Y Yamada, T Hamaguchi, M Goto, K Muro, Y Matsumura, Y Shimada, K Shirao, S Nagayama. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
British journal of cancer.
2003 Sep; 89(5):816-20. doi:
10.1038/sj.bjc.6601224. [PMID: 12942110] - G J Peters, P Noordhuis, A B P Van Kuilenburg, J H Schornagel, H Gall, S L Turner, M S Swart, D Voorn, A H Van Gennip, J Wanders, U Holwerda, K Smid, G Giaccone, P Fumoleau, C J Van Groeningen. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Cancer chemotherapy and pharmacology.
2003 Jul; 52(1):1-12. doi:
10.1007/s00280-003-0617-9. [PMID: 12739060] - Kenji Omura. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
International journal of clinical oncology.
2003 Jun; 8(3):132-8. doi:
10.1007/s10147-003-0330-z. [PMID: 12851836] - Y Mizutani, H Wada, O Yoshida, M Fukushima, H Nakanishi, M Nakao, T Miki. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
European journal of cancer (Oxford, England : 1990).
2003 Mar; 39(4):541-7. doi:
10.1016/s0959-8049(02)00730-x. [PMID: 12751387] - D Korenaga, M Honda, M Yasuda, S Inutsuka, T Nozoe, H Tashiro. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes.
2002 Sep; 34(5):351-6. doi:
10.1159/000064001. [PMID: 12364819] - Masataka Ikeda, Hiroshi Furukawa, Hiroshi Imamura, Jyunzo Shimizu, Hideyuki Ishida, Seizo Masutani, Masayuki Tatsuta, Takatoshi Kawasaki, Takashi Satomi. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Cancer chemotherapy and pharmacology.
2002 Jul; 50(1):25-32. doi:
10.1007/s00280-002-0457-z. [PMID: 12111108] - T Takechi, A Fujioka, E Matsushima, M Fukushima. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
European journal of cancer (Oxford, England : 1990).
2002 Jun; 38(9):1271-7. doi:
10.1016/s0959-8049(02)00048-5. [PMID: 12044515] - Satoshi Daigo, Yoshiki Takahashi, Masaki Fujieda, Noritaka Ariyoshi, Hiroshi Yamazaki, Wasaburo Koizumi, Satoshi Tanabe, Katsunori Saigenji, Sekio Nagayama, Kazumasa Ikeda, Yasuhiko Nishioka, Tetsuya Kamataki. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Pharmacogenetics.
2002 Jun; 12(4):299-306. doi:
10.1097/00008571-200206000-00005. [PMID: 12042667] - K Yoshisue, S Nagayama, T Shindo, Y Kawaguchi. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats.
The Journal of pharmacology and experimental therapeutics.
2001 Jun; 297(3):1166-75. doi:
. [PMID: 11356943] - E Matsushima, K Yoshida, R Kitamura, K Yoshida. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Mar; 691(1):95-104. doi:
10.1016/s0378-4347(96)00429-x. [PMID: 9140762] - T Hayashi, G Tanaka, K Irimura, T Hirota, S Ohmae. [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
The Journal of toxicological sciences.
1996 Nov; 21 Suppl 3(?):495-504. doi:
10.2131/jts.21.supplementiii_495. [PMID: 9021658] - A Ohuchida, Y Kouchi, S Sato, Y Maeda. [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
The Journal of toxicological sciences.
1996 Nov; 21 Suppl 3(?):675-89. doi:
10.2131/jts.21.supplementiii_675. [PMID: 9021668]